Search

Author/Creator Padilla, Francisco

1. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Issue 15 (14th April 2020)

Authors:
Zelniker, Thomas A.; Bonaca, Marc P.; Furtado, Remo H.M.; Mosenzon, Ofri; Kuder, Julia F.; Murphy, Sabina A.; Bhatt, Deepak L.; Leiter, Lawrence A.; McGuire, Darren K.; Wilding, John P.H.; Budaj, Andrzej; Kiss, Robert G.; Padilla, Francisco; Gause-Nilsson, Ingrid; Langkilde, Anna Maria; Raz, Itam...
Journal:
Circulation
Issue:
Volume 141:Issue 15(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Issue 10 (October 2022)

Authors:
Montgomery, Hugh; Hobbs, F D Richard; Padilla, Francisco; Arbetter, Douglas; Templeton, Alison; Seegobin, Seth; Kim, Kenneth; Campos, Jesus Abraham Simón; Arends, Rosalinda H; Brodek, Bryan H; Brooks, Dennis; Garbes, Pedro; Jimenez, Julieta; Koh, Gavin C K W; Padilla, Kelly W; Streicher, Katie; V...
Journal:
Lancet
Issue:
Volume 10:Issue 10(2022)
Page Start:
985
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1918. Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial. (15th December 2022)

Authors:
Campos, Jesus Abraham Simón; Arbetter, Douglas; Montgomery, Hugh; Richard Hobbs, F D; Padilla, Francisco; Kim, Kenneth; Streicher, Katie; Templeton, Alison; Viani, Rolando M; Esser, Mark T
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial. (15th December 2022)

Authors:
Richard Hobbs, F D; Montgomery, Hugh; Padilla, Francisco; Kim, Kenneth; Simón Campos, Jesus Abraham; Arbetter, Douglas; Padilla, Kelly W; Reddy, Venkatesh P; Seegobin, Seth; Streicher, Katie; Viani, Rolando M; Koh, Gavin C KW; Esser, Mark T
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults. (15th December 2022)

Authors:
Kijak, Gustavo H; Ahani, Bahar; Arbetter, Douglas; Brady, Tyler; Chuecos, Fernando; Gopalakrishnan, Vancheswaran; Roe, Tiffany L; Schuko, Nicolette; Richard Hobbs, F D; Padilla, Francisco; Kelly, Elizabeth J; Montgomery, Hugh; Streicher, Katie
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗